Although some studies have investigated nAMD patients with delayed treatment due to COVID-19, to our knowledge, this is the first study to evaluate the clinical prognosis, including the quantitative analysis of anatomical abnormalities, by tracking nAMD patients with delayed intravitreal anti-VEGF injections due to COVID-19 for up to 6 months after the delayed injection date. The gene discussed is VEGFA; the disease is COVID-19.